Skelaxin: Targeted Muscle Spasm Relief with Minimal Sedation
| Product dosage: 400mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.48 | $74.37 (0%) | 🛒 Add to cart |
| 60 | $1.96 | $148.73 $117.58 (21%) | 🛒 Add to cart |
| 90 | $1.78 | $223.10 $159.78 (28%) | 🛒 Add to cart |
| 120 | $1.69 | $297.46 $203.00 (32%) | 🛒 Add to cart |
| 180 | $1.60 | $446.19 $288.42 (35%) | 🛒 Add to cart |
| 270 | $1.55
Best per pill | $669.29 $419.06 (37%) | 🛒 Add to cart |
Synonyms | |||
Skelaxin (metaxalone) is a centrally acting skeletal muscle relaxant indicated for the treatment of acute, painful musculoskeletal conditions. It functions by depressing polysynaptic reflexes in the spinal cord and subcortical areas of the brain, leading to reduced muscle hyperactivity without complete paralysis. Unlike many other agents in its class, Skelaxin is noted for its favorable side effect profile, particularly its lower incidence of pronounced sedation, making it a preferred option for patients requiring functional alertness during treatment. This monograph provides a comprehensive overview of its pharmacological profile, clinical application, and safety considerations for healthcare professionals.
Features
- Active ingredient: Metaxalone 800 mg
- Pharmacologic class: Centrally acting skeletal muscle relaxant
- Mechanism of action: Depression of polysynaptic reflexes
- Dosage form: Oral tablet
- Recommended dosing: Up to four times daily
- Prescription status: Rx-only medication
- Onset of action: Typically within one hour
- Duration of effect: 4–6 hours per dose
Benefits
- Provides effective relief from acute, painful muscle spasms by reducing reflex hyperactivity.
- Offers a more favorable sedation profile compared to other muscle relaxants, supporting patient functionality.
- Facilitates improved range of motion and participation in physical therapy.
- Helps break the cycle of pain-spasm-pain, accelerating recovery.
- Simple dosing regimen supports patient adherence.
- May be used as part of a comprehensive treatment plan including rest and physical therapy.
Common use
Skelaxin is primarily prescribed for the adjunctive treatment of acute, painful musculoskeletal conditions characterized by muscle spasm. It is most commonly used in cases of back pain, neck pain, sprains, strains, and other trauma-related musculoskeletal injuries. It is intended for short-term use, typically not exceeding two to three weeks, as part of a multimodal approach that may include rest, physical therapy, analgesics, and other supportive measures. It is not indicated for chronic musculoskeletal disorders or spasticity associated with cerebral or spinal cord pathologies.
Dosage and direction
The recommended adult dosage of Skelaxin is 800 mg taken three to four times daily. Tablets should be swallowed whole with a full glass of water and may be taken with or without food, though administration with food may enhance tolerability in some patients. The duration of therapy should be limited to the acute painful period, generally not exceeding 2–3 weeks, as sufficient evidence for longer-term use is lacking. Dosage adjustment in renal or hepatic impairment has not been established; use with caution in these populations.
Precautions
Patients should be cautioned about operating machinery, driving, or engaging in hazardous activities until they know how Skelaxin affects them, as it may cause drowsiness, dizziness, or lightheadedness. Concurrent use with alcohol, sedatives, hypnotics, or other CNS depressants may potentiate these effects. Use with caution in patients with hepatic or renal impairment due to limited elimination data. Skelaxin may cause false-positive Benedict’s tests for urinary reducing substances due to its metabolite excretion. Safety and effectiveness in pediatric patients have not been established.
Contraindications
Skelaxin is contraindicated in patients with a known hypersensitivity to metaxalone or any component of the formulation. It is also contraindicated in patients with a tendency to drug-induced, hemolytic, or other anemias, and in those with significantly impaired renal or hepatic function. Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy is contraindicated due to potential serotonin syndrome risk.
Possible side effect
The most commonly reported adverse reactions (≥3%) include drowsiness, dizziness, headache, nervousness, and nausea. Less frequently, vomiting, gastrointestinal upset, and rash may occur. Serious side effects are rare but may include hypersensitivity reactions (urticaria, pruritus, rash), hemolytic anemia, and jaundice. Patients should discontinue use and seek medical attention if they experience signs of an allergic reaction, yellowing of the skin or eyes, or unusual tiredness.
Drug interaction
Skelaxin may enhance the sedative effects of alcohol, benzodiazepines, opioids, tricyclic antidepressants, and other CNS depressants. Concomitant use with MAOIs is contraindicated. Caution is advised when using with other serotonergic drugs due to theoretical serotonin syndrome risk, though clinical reports are limited. Metaxalone is primarily metabolized by the liver via CYP pathways, and interactions with strong CYP inhibitors or inducers are possible, though not well-documented.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one.
Overdose
Overdose may manifest as exaggerated CNS depression, including severe drowsiness, lethargy, coma, and respiratory depression. Cardiovascular effects such as hypotension and tachycardia may also occur. Management is supportive and symptomatic, including gastric lavage if presented early, activated charcoal, and careful monitoring of vital signs. There is no specific antidote; hemodialysis is unlikely to be beneficial due to high protein binding.
Storage
Store Skelaxin tablets at controlled room temperature, 20°–25°C (68°–77°F), with excursions permitted between 15°–30°C (59°–86°F). Keep in the original container, tightly closed, and protect from light and moisture. Keep out of reach of children and pets. Properly discard any expired or unused medication.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.
Reviews
Clinical studies and post-marketing surveillance indicate that Skelaxin is generally well-tolerated and effective for its indicated use. Many clinicians appreciate its lower sedative burden compared to alternatives like cyclobenzaprine or carisoprodol, making it suitable for working patients. Patient reports often highlight effective spasm relief with less daytime drowsiness. However, individual responses vary, and some patients may not experience adequate relief or may encounter side effects. It remains a valuable option within the muscle relaxant class when used appropriately for acute conditions.